Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson Sells 4,825 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 4,825 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $16.26, for a total value of $78,454.50. Following the transaction, the director now owns 3,702,595 shares of the company’s stock, valued at $60,204,194.70. This trade represents a 0.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Tyra Biosciences Trading Down 2.4 %

Shares of NASDAQ TYRA opened at $15.50 on Tuesday. Tyra Biosciences, Inc. has a 1-year low of $12.48 and a 1-year high of $29.60. The company has a 50-day moving average of $15.38 and a two-hundred day moving average of $19.12. The company has a market cap of $784.35 million, a PE ratio of -9.63 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in TYRA. Janus Henderson Group PLC bought a new position in Tyra Biosciences in the third quarter valued at about $24,994,000. Perceptive Advisors LLC boosted its stake in shares of Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares during the last quarter. Walleye Capital LLC grew its position in shares of Tyra Biosciences by 306.5% during the 3rd quarter. Walleye Capital LLC now owns 126,597 shares of the company’s stock worth $2,976,000 after buying an additional 95,451 shares during the period. Polar Asset Management Partners Inc. bought a new stake in shares of Tyra Biosciences during the third quarter worth approximately $2,071,000. Finally, FMR LLC lifted its holdings in Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after buying an additional 26,187 shares during the period. Institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

TYRA has been the subject of a number of analyst reports. Wedbush reissued an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a report on Friday, October 25th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, January 13th. Bank of America raised shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $22.00 to $31.00 in a report on Friday, October 18th. Finally, UBS Group assumed coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences presently has a consensus rating of “Buy” and an average target price of $30.50.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.